Sonoma Pharmaceuticals Business Summary

Sonoma Pharmaceuticals, Inc. (SNOA) operates as a global healthcare leader specializing in the development and commercialization of stabilized hypochlorous acid (HOCl) products powered by its patented Microcyn® technology. The company generates revenue primarily through the sale of over-the-counter (OTC) and prescription-strength solutions across two primary business segments: Human Health—encompassing wound care, dermatology, eye, oral, and nasal care—and Animal Health. Revenue is driven by a multi-channel distribution strategy that includes direct sales to major retailers like Walmart, partnerships with healthcare distributors such as Medline Industries, and international manufacturing orders in over 55 countries. Sonoma competes directly with small-cap medical and pharmaceutical firms such as VYNE Therapeutics, Synergy CHC, Phio Pharmaceuticals, and Lunai Bioworks, positioning itself as the specialized market leader in high-stability HOCl formulations with an extensive global regulatory portfolio. Leadership is spearheaded by CEO Amy Trombly, a corporate and securities law expert who previously served as Special Counsel at the U.S. Securities and Exchange Commission and Vice President at State Street Bank. The executive team was significantly strengthened in early 2026 with the appointment of Arturo Angel as Senior Vice President of Regulatory, Quality, and Product Development, bringing over 15 years of R&D leadership from Bausch Health. The Board of Directors includes Lead Independent Director Jerry McLaughlin and newly appointed Audit Committee Chair Vanessa Jacoby, who currently serves as Chief Business and Financial Officer at Quanta Therapeutics and formerly held senior roles at Shoreline Biosciences and Avidity Biosciences. This leadership core combines deep regulatory pedigree with financial expertise to scale the company’s manufacturing operations in Mexico and its commercial headquarters in the Netherlands and the United States.